Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review  

作　　者：Rogelio González-González Sandra López-Verdín Jesús Lavalle-Carrasco Nelly Molina-Frechero Mario Isiordia-Espinoza Ramón G Carreón-Burciaga Ronell Bologna-Molina 

机构地区：[1]Department of Research,School of Dentistry,Universidad Juárez del Estado de Durango,Durango 34000,Mexico [2]Research Institute of Dentistry,Health Science Center,Universidad de Guadalajara,Guadalajara 4430,Mexico [3]Department of Health Care,Xochimilco Unit,Universidad Autónoma Metropolitana Xochimilco,México 04960,Mexico [4]Department of Clinics,Biomedical Sciences Division,Centro Universitario de los Altos,Universidad de Guadalajara,Tepetitlán de Morelos 47620,Mexico [5]Molecular Pathology Area,School of Dentistry,Universidad de la República,Montevideo 11600,Uruguay

出　　处：《World Journal of Clinical Oncology》2020年第1期31-42,共12页世界临床肿瘤学杂志（英文版）

摘　　要：BACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies.Different signaling pathways that participate in the progression of these tumors have been identified.B-raf proto-oncogene serine/threonine kinase(BRAF)is a protein involved in the behavior of ameloblastomas,and it is related to many cell mechanisms.BRAF gene mutations have been identified in ameloblastomas,of which the BRAF V600E(valine substituted by glutamic acid at amino acid 600)mutation has been the most common and can be present concomitantly with other mutations that may be involved in its behavior.Targeted therapies have been used as an alternative in the case of resistance or contraindications to conventional treatments.AIM To document the presence of BRAF V600E and additional mutations,their behavior,and targeted therapies in these tumors.METHODS An electronic literature search was conducted according to PRISMA guidelines in PubMed/MEDLINE,Cochrane,EMBASE,and SpringerLink using the terms“ameloblastomas”,“BRAF V600E”,“additional mutations”,and“targeted therapies”.Ameloblastomas were classified according to WHO guidelines.Inclusion criteria were articles in English,published not more than 10 years ago,and studies with laboratory works related to BRAF V600E.Articles were evaluated by two independent reviewers and retrieved for full-text evaluation.The EBLIP Critical Appraisal Checklist was used to evaluate the quality of the eligible studies.Descriptive statistical analysis was performed.RESULTS Two independent reviewers,with a substantial concordance indicated by a kappa coefficient of k=0.76,evaluated a total of 19 articles that were included in this study.The analysis registered 521 conventional ameloblastomas(AM),81 unicystic ameloblastomas(UA),13 ameloblastic carcinomas(AC),three metastatic ameloblastomas(MA),and six peripheral ameloblastomas(PA),of which the histopathological type,anatomic location,laboratory tests,expBACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies. Different signaling pathways that participate in the progression of these tumors have been identified. B-raf proto-oncogene serine/threonine kinase(BRAF) is a protein involved in the behavior of ameloblastomas, and it is related to many cell mechanisms. BRAF gene mutations have been identified in ameloblastomas, of which the BRAF V600E(valine substituted by glutamic acid at amino acid 600) mutation has been the most common and can be present concomitantly with other mutations that may be involved in its behavior.Targeted therapies have been used as an alternative in the case of resistance or contraindications to conventional treatments.AIM To document the presence of BRAF V600E and additional mutations, their behavior, and targeted therapies in these tumors.METHODS An electronic literature search was conducted according to PRISMA guidelines in Pub Med/MEDLINE, Cochrane, EMBASE, and Springer Link using the terms"ameloblastomas", "BRAF V600E", "additional mutations", and "targeted therapies". Ameloblastomas were classified according to WHO guidelines.Inclusion criteria were articles in English, published not more than 10 years ago,and studies with laboratory works related to BRAF V600E. Articles were evaluated by two independent reviewers and retrieved for full-text evaluation.The EBLIP Critical Appraisal Checklist was used to evaluate the quality of the eligible studies. Descriptive statistical analysis was performed.RESULTS Two independent reviewers, with a substantial concordance indicated by a kappa coefficient of k = 0.76, evaluated a total of 19 articles that were included in this study. The analysis registered 521 conventional ameloblastomas(AM), 81 unicystic ameloblastomas(UA), 13 ameloblastic carcinomas(AC), three metastatic ameloblastomas(MA), and six peripheral ameloblastomas(PA), of which the histopathological type, anatomic location, la

关 键 词：AMELOBLASTOMA B-raf proto-oncogene serine/threonine kinase B-raf protooncogene serine/threonine kinase V600E Additional mutations Targeted therapies 

分 类 号：R73[医药卫生—肿瘤]